AB
Insider
Ali Behbahani
DirectorAli Behbahani (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in ADAP. Across 1 priced purchase filing, the average 21-session return was +6.2% from execution and -5.7% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of SGP (937,500 sh × $16.00, as filed), executed Feb 9.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+6.2%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-5.7%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$15.8M
shares × price, as filed
Last traded
Sep 17
Filed yesterday
Median ADV $94.8M across their filed names
Open performance→Volume by month
Buys $15.0M
Sells $928K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Not on file
1 filing
Sector per market data · by filing · past 12 months
Most traded names
ADAP
ADAP
ADAP · 0 buys · 1 sell
1 filing
SGP
SGP
SGP · 1 buy · 0 sells
1 filing
Recent filings
CRSPSALE
CRISPR Therapeutics AG
View filing →
$781K13,679 sh × $57.09
Exec Sep 17
Filed Sep 21 · 6:40 PM ET SGPPURCHASE SpyGlass Pharma, Inc. View filing → $15.0M
937,500 sh × $16.00
Exec Feb 9
Filed Feb 11 · 4:30 PM ET ADAPSALE Adaptimmune Therapeutics PLC View filing → $147K
14,671,794 sh × $0.01
Exec Aug 18 2025
Filed Aug 19 2025 · 5:30 PM ET MBXPURCHASE MBX Biosciences, Inc. View filing → $8.0M
500,000 sh × $16.00
Exec Sep 16 2024
Filed Sep 17 2024 · 5:30 PM ET